Retinal amyloid in Alzheimer's disease

Not Applicable

• Conditions: Alzheimer disease, mild cognitive impairment; dementia; D000544, D060825

• Registration Number: JPRN-jRCTs061190024
• Lead Sponsor: Yamashita Toru

Brief Summary

The present noninvasive in vivo detection of retinal amyloid deposition is useful for screening AD patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-11-25
• Study Completion: 2020-12-07
• Results First Posted: 2021-09-14
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

1. Outpatient of the neurology department of our clinic
2. Diagnosed as Alzheimer's disease, mild cognitive impairment(MCI), or normal cognitive function (except for complication of vascular dementia)
3. Native Japanese speaker
4. Age from 65 to 84

Exclusion Criteria

1. Impossible to take crucumin supplement due to severe dysphagia
2. Diagnosed as closed-angle glaucoma, and impossible to use mydriatic agent
3. Severe visual impairment requiring daily support
4. Unable to take curcumin supplement or examination due to severe cognitive decline
5. Judged by researchers not to be eligible

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
retinal amyloid deposition

Secondary Outcome Measures

Name	Time	Method
1. Background of participants<br>2. Cognitive function test<br>3. Brain MRI<br>4. Cerebral blood flow measured by SPECT<br>5. Amyloid PET<br>6. Adverse events<br>7. Compliance of curcumin